OPK
(NASDAQ)
1.42
+0.0520  (+3.68%)
Volume (24h): 9.47M Day Range: 1.38 - 1.45
Market Cap: 947.94M 52W Range: 1.33 - 2.91
Mar-27-20 03:31PM Why Is OPKO Health (OPK) Down 4.2% Since Last Earnings Report?Zacks
Mar-25-20 12:00PM OPKO Health Reports Interim Results for Two Ongoing RAYALDEE StudiesGlobeNewswire
06:29AM OPKO's BioReference Laboratories Widens COVID-19 Testing (Revised)Zacks
Mar-24-20 06:30PM Opko Health subsidiary partners with City of Miami on coronavirus testingAmerican City Business Journals
01:00PM OPKO Health's BioReference Laboratories and City of Miami Provide Testing for Coronavirus Disease 2019 (COVID-19)PR Newswire
Mar-24-20 12:43PM OPKO's BioReference Laboratories Widens COVID-19 TestingZacks
Mar-23-20 02:05PM OPKO's BioReference Laboratories Offers COVID-19 TestingZacks
11:00AM OPKO Health's BioReference Laboratories and City of Detroit Provide Testing for Coronavirus Disease 2019 (COVID-19)PR Newswire
Mar-20-20 03:54PM OPKO Health's BioReference Laboratories and State of New Jersey Provide Testing for Coronavirus Disease 2019 (COVID-19)PR Newswire
Mar-17-20 06:26PM OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19)PR Newswire
Mar-13-20 02:53PM The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches AntiviralsBenzinga
12:13PM Benzinga Pro's Top 5 Stocks To Watch For Fri., Mar. 13, 2020: GLD, OPK, IBIO, CPB, CANFBenzinga
Mar-13-20 11:48AM South Florida biotech company launches testing for coronavirusAmerican City Business Journals
11:43AM Opko's stock soars on plans for COVID-19 testing sites in New YorkMarketWatch
Mar-13-20 11:00AM OPKO's BioReference Laboratories Offers Testing for Coronavirus Disease 2019 (COVID-19)PR Newswire
Mar-11-20 04:48PM Edited Transcript of OPK earnings conference call or presentation 26-Feb-20 9:30pm GMTThomson Reuters StreetEvents
02:15PM OPK Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Investigation of OPKO Health, Inc. and Encourages Investors to Contact the FirmACCESSWIRE
Mar-11-20 11:51AM Edited Transcript of OPK earnings conference call or presentation 26-Feb-20 9:30pm GMTThomson Reuters StreetEvents
09:28AM South Floridians banned from penny stocks after $27M fraudAmerican City Business Journals
Mar-10-20 08:32PM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of OPKO Health, Inc. – OPKGlobeNewswire
04:30AM Edited Transcript of OPK earnings conference call or presentation 26-Feb-20 9:30pm GMTThomson Reuters StreetEvents
Mar-09-20 09:42PM Edited Transcript of OPK earnings conference call or presentation 26-Feb-20 9:30pm GMTThomson Reuters StreetEvents
01:36PM Company News for Mar 9, 2020Zacks
Mar-06-20 06:57PM OPK Stock Rockets 13% Higher on Coronavirus Test AnnouncementInvestorPlace
02:25PM Implied Volatility Surging for OPKO Health (OPK) Stock OptionsZacks
Mar-05-20 05:30PM OPKO Health's BioReference Laboratories to Introduce Coronavirus Disease (COVID-19) TestPR Newswire
12:23PM Here's Why You Should Hold on to OPKO Health Stock for NowZacks
Feb-28-20 03:20PM OPKO Health, Inc. Just Reported Earnings, And Analysts Cut Their Target PriceSimply Wall St.
Feb-27-20 02:47PM OPKO Health (OPK) Q4 Loss Narrower Than Estimates, Sales UpZacks
Feb-26-20 11:35PM OPKO Health (OPK) Reports Q4 Loss, Tops Revenue EstimatesZacks
09:05PM OPKO Health Reports 2019 Fourth Quarter Business Highlights and Financial ResultsGlobeNewswire
Feb-24-20 03:51PM Weekly CEO Buys HighlightGuruFocus.com
Feb-20-20 05:15PM OPKO Health to Report Fourth Quarter 2019 Financial Results on February 26, 2020GlobeNewswire
Feb-19-20 05:31PM OPKO Health (OPK) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks
Feb-08-20 02:11PM Our Take On OPKO Health, Inc.'s (NASDAQ:OPK) CEO SalarySimply Wall St.
Feb-03-20 03:28PM Weekly CEO Buys HighlightGuruFocus.com
01:46PM Here's Why You Should Hold on to OPKO Health Stock for NowZacks
Jan-27-20 03:36PM Weekly CEO Buys HighlightGuruFocus.com
Jan-20-20 04:02PM Weekly CEO Buys HighlightGuruFocus.com
Jan-13-20 04:01PM Weekly CEO Buys HighlightGuruFocus.com
Jan-06-20 03:40PM Weekly CEO Buys HighlightGuruFocus.com
Dec-30-19 07:44PM Weekly CEO Buys HighlightGuruFocus.com
Dec-27-19 03:04PM Here's Why You Should Retain OPKO Health (OPK) Stock for NowZacks
Dec-19-19 05:00PM BioReference Laboratories Showcases 2019 Growth through the Addition of Cutting Edge Tests, Greater Access to Services, and Optimized Patient ExperienceGlobeNewswire
01:00PM OPKO Health to Present at the 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
Dec-16-19 04:28PM Weekly CEO Buys HighlightGuruFocus.com
Dec-13-19 05:52PM Is Opko Health Inc. (OPK) Going to Burn These Hedge Funds?Insider Monkey
Dec-10-19 05:00PM The OPKO Health (NASDAQ:OPK) Share Price Is Down 86% So Some Shareholders Are Rather UpsetSimply Wall St.
Dec-09-19 03:49PM Weekly CEO Buys HighlightGuruFocus.com
Dec-05-19 04:31PM Why Is OPKO Health (OPK) Up 10.8% Since Last Earnings Report?Zacks
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)